Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study.
Conclusion: This analysis of real-world data indicates that the effectiveness of CT-P13 is equivalent to that of RP for infliximab-naive patients with CD. No difference was observed for safety outcomes.
Primary Funding Source: Caisse Nationale de l'Assurance Maladie.
PMID: 30534946 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Meyer A, Rudant J, Drouin J, Weill A, Carbonnel F, Coste J Tags: Ann Intern Med Source Type: research
More News: Cancer | Cancer & Oncology | Crohn's Disease | Databases & Libraries | France Health | Hematology | Inflammatory Bowel Disease | Internal Medicine | Remicade | Rheumatology | Study | Tuberculosis